Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
GlaxoSmithKline will pay up to $508 million for access to Amplimmune’s protein fusion therapies that target PD-1, a protein involved in regulating T-cell-mediated immune responses. Rockville, Md.-based Amplimmune scores $23 million up front and is eligible for milestones as its lead candidate, AMP-224, progresses in clinical trials. Amplimmune expects to file an Investigational New Drug Application with FDA and start a Phase I clinical trial of AMP-224 for treatment of cancer in 2011.
This article has been sent to the following recipient: